Evidence map›Paper›PMID 32913996›Full record

ArticleJCO precision oncology2018

Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study.

Anita Chawla, Filip Janku, Jennifer J Wheler, Vincent A Miller, Jason Ryan, Rachel Anhorn, Zhou Zhou, James Signorovitch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anita Chawla, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
Filip Janku, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
Jennifer J Wheler, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
Vincent A Miller, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
Jason Ryan, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
Rachel Anhorn, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
Zhou Zhou, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.
James Signorovitch, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeComprehensive genomic profiling (CGP) detects several classes of genomic alterations across numerous genes simultaneously and can match more patients with genomically targeted therapies than conventional molecular profiling. The current study estimated the costs of anticancer drugs and overall survival (OS) for patients who were treated with matched and unmatched therapy.

methodsCosts were estimated for patients with complete data (188 of 500 patients) from a prospective, nonrandomized study of patients with diverse refractory cancers who underwent CGP and were treated with matched or unmatched therapy. We assessed mean time to treatment failure (TTF) and mean observed OS. Patient-specific drug and administration costs were imputed for the first regimen after CGP on the basis of drug classes, unit costs, and time on treatment.

resultsPatients on matched (n = 122) versus unmatched (n = 66) therapy had longer mean TTF (+1.5 months) and observed OS (+2.4 months) and higher drug costs (+$38,065; all

conclusionMatched therapy was associated with longer TTF, increased OS, and manageable incremental cost increases compared with unmatched therapy. Most of these increased costs were a result of the longer duration of therapy rather than higher monthly drug costs. The benefits of matching were numerically greater in earlier versus later lines of therapy, which is consistent with the value of early use of CGP.

Identifiers

PMID32913996
PMCPMC7446484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.